ABSTRACT

The harmful effects of 14 chemotherapeutic drugs on spermatogenesis in the mouse have been evaluated by studies of testicular cell killing and morphological and genetic damage produced. Male mice were given drugs as single injections at various doses up to the toxic levels. Prednisone and 6-mercaptopurine produced little or no cytotoxicity. All other drugs tested killed differentiated spermatogonia. Of these, methotrexate, cyclohexylchloroethylnitrosourea, cis-platinum, and mechlorethamine did not show significant stem cell killing. Bischloroethylnitrosourea, chlorambucil, 5-fluorouracil, mitomycin C, actinomycin D, and procarbazine showed some stem cell killing. Triethylenethiophosphoramide (thio-TEPA) was the only drug in this group which killed large numbers of stem cells. Only 5-fluorouracil and cis-platinum killed spermatocytes, and only cis-platinum killed spermatids. Several drugs induced chromosomal breaks in treated spermatocytes. Thio-TEPA was effective in inducing chromosome translocations in treated spermatocytes and probably also in spermatocytes which originated from surviving treated stem cells. It had been our hypothesis that the cytotoxic effects of these drugs on mouse testicular stem cells would correlate with the duration of azoospermia observed in patients. This was shown not to be the case. Thus, the cytotoxic effects of single injections of single chemotherapeutic agents on the mouse testis did not appear to be predictive of which drugs will cause long-term azoospermia in humans.

INTRODUCTION

Permanent azoospermia and sterility is now recognized as a common side effect of cancer chemotherapy in humans (43). An evaluation of which drugs are responsible for this damage would provide valuable information to the clinician. The use of drugs with lower toxicity to testicular cells may then be considered in the treatment of patients of reproductive age who have reasonable prognoses. This is very difficult to evaluate from clinical data, since combination chemotherapy is now used almost exclusively. An experimental test system is needed. Since spermatogonial stem cell survival appears, at least in the mouse, to provide a measure of the duration and permanence of radiation- or chemotherapy-induced sterility and oligozoospernia (32), that parameter was chosen for screening the sterilizing effect of chemotherapeutic agents.

In a previous study (27), single injections of 7 chemotherapeutic drugs (ADR,7 bleomycin, cyclophosphamide, 1β-D-arabinofuranosycytosine, hydroxyurea, vinblastine, and vincristine) were given to mice. Survival levels of stem spermatogonia, differentiated spermatogonia, and other testicular cells were measured. As a next step in these studies, we have applied these same techniques to 14 additional common chemotherapeutic agents. In addition, we have also obtained some preliminary information as to the genetic toxicity of several of these agents. The rationale for this approach is that, since nearly all chemotherapeutic drugs will cause some cytotoxic and genotoxic effects on spermatogenic cells, it is only by applying the same methods to a spectrum of drugs that quantitative information on the effects of different drugs can be obtained. One goal of this study was to determine whether or not the stem cell cytotoxicity of single injections of single agents given to mice can predict the clinical results observed in humans.

Various end points could be used to assess long-term effects on fertility. Measurement of stem cell survival was considered to be most important since all differentiated cells leave the testis within 45 days. The sperm count assay for stem cell survival was chosen since it is more sensitive and rapid than fertility testing and is highly correlated with fertility (32). In general, biochemical tests have not been able to predict the effects of these drugs on sperm production and fertility, although they provide information such as mechanisms of drug action and its testicular penetration and activity. Gross histology of the testis is often of little value unless high levels of damage are observed. Quantitative germ cell counts are tedious and were not considered necessary, since striking effects of nearly all drugs were detected by sperm counts. However, semiquantitative histological analysis of each individual stage of the seminiferous epithelial cycle is more rapid and can provide a comparison of the different stages of spermatogenesis upon which these drugs act, to use as a basis for future studies of mechanisms of cytotoxicity.

A variety of methods can be used to study mutagenic effects of chemotherapy. Biochemical assays (e.g., unscheduled DNA synthesis) may provide mechanistic information but would not provide any information regarding events in stem cells. Muta-

---

1 This investigation was supported by Grants CA-17364 and CA-06294, awarded by the National Cancer Institute, Department of Health, Education, and Welfare. Animals used in this study were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the United States Department of Health, Education, and Welfare, NIH.

2 Present address: Fachklinik Hornheide, Universitaet Muenster, Muenster, West Germany.

3 Present address: Biology Division, Oak Ridge National Laboratory, P. O. Box Y, Oak Ridge, Tenn. 37830.

Received April 29, 1981; accepted September 10, 1981.

4 The abbreviations used are: ADR, Adriamycin; LD50, 50% lethal dose; MTX, methotrexate; PCB, procarbazine; BCNU, bischloroethylnitrosourea; PRED, prednisone; THIO, triethylenethiophosphoramide; CCNU, cyclohexylchloroethylnitrosourea; 5-FU, 5-fluorouracil; CDDP, cis-diamminedichloroplatinum II; HN2, mechlorethamine; MTC, mitomycin C; ACT, actinomycin D; DNR, daunorubicin; 6-MP, 6-mercaptopurine; CHL, 6-aminoguaninethiopurine; MOPP, mechlorethamine-vincristine-dimethoxyzene-prednisone combination therapy; MVPP, mechlorethamine-vincristine-procarbazine-prednisone combination therapy.
genicity assays involving breeding and analysis of the offspring are most desirable but are expensive and time consuming. We have, therefore, chosen the spermatocyte translocation assay to measure the genotoxic effects of chemotherapeutic drugs. This assay can measure effects on stem cells and is correlated with chromosomal abnormalities in fetuses produced by breeding the treated male.

In this study, drugs were administered i.v. or i.p. Data obtained using such routes can be directly compared with clinical data. In contrast, studies which use intratesticular injection cannot be compared. Administration p.o. of certain drugs might have been preferable but was not done here.

Drugs were given as single injections of single chemotherapeutic agents. This simple protocol may not be directly comparable to the clinical situation. Differences in sensitivity between slowly cycling stem cells in the unperturbed testis and the regenerating stem cells that are recovering from a cytotoxic insult may exist. Nevertheless, this study should provide baseline information necessary to compare with the effects of protracted treatments.

**MATERIALS AND METHODS**

**Mice**

C3H mice were used throughout. In most experiments, C3Hf/Kam mice maintained in our own specific pathogen-free colony were used. In some experiments, however, C3HHe/FeJ (The Jackson Laboratory, Bar Harbor, Maine), C3H/HeTex (Timco, Houston, Texas), or C3Hf/Sed (Massachusetts General Hospital, Boston, Mass.) were used. No differences between substrains were observed.

**Drugs**

The drugs used and their sources, preparation, and modes of injection are listed in Table 1. If the drug was injected with ethanol or Klucell

**Table 1**

Summary of drugs used

<table>
<thead>
<tr>
<th>Drug</th>
<th>Other identification</th>
<th>Source*</th>
<th>Preparation procedure</th>
<th>Mode of injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>Cosmegen, dactinomycin</td>
<td>Merck, Sharp and Dohme, West Point, Pa.</td>
<td>b</td>
<td>i.v.</td>
</tr>
<tr>
<td>BCNU</td>
<td>BiCNU, carmustine</td>
<td>Bristol Laboratories, Syracuse, N. Y.</td>
<td>b</td>
<td>i.p.</td>
</tr>
<tr>
<td>CCNU</td>
<td>Lomustine</td>
<td>Bristol Laboratories, Syracuse, N. Y.</td>
<td>d</td>
<td>i.p.</td>
</tr>
<tr>
<td>CDCP</td>
<td>cis-Platinum (NSC 119875)</td>
<td>Drug Synthesis and Chemistry Branch, Division of Cancer Treatment, National Cancer Institute</td>
<td>f</td>
<td>i.p., i.v.</td>
</tr>
<tr>
<td>DNR</td>
<td>Daunomycin (NSC 82151)</td>
<td>Division of Cancer Treatment, National Cancer Institute</td>
<td>b</td>
<td>i.v.</td>
</tr>
<tr>
<td>5-FU</td>
<td>Mustargen, nitrogen mustard</td>
<td>Roche Laboratories, Nutley, N. J.</td>
<td>b</td>
<td>i.p., i.v.</td>
</tr>
<tr>
<td>HN2</td>
<td>Merck, Sharp and Dohme, West Point, Pa.</td>
<td>b</td>
<td>i.p., i.v.</td>
<td></td>
</tr>
<tr>
<td>6-MP</td>
<td>Purinethol (NSC 755)</td>
<td>Division of Cancer Treatment, National Cancer Institute</td>
<td>b</td>
<td>i.p., i.v.</td>
</tr>
<tr>
<td>MTX</td>
<td>Amethopterin</td>
<td>Lederle Laboratories, Pearl River, N. Y.</td>
<td>b</td>
<td>i.p.</td>
</tr>
<tr>
<td>MTC</td>
<td>Mutamycin</td>
<td>Bristol Laboratories, Syracuse, N. Y.</td>
<td>b</td>
<td>i.p.</td>
</tr>
<tr>
<td>PCB</td>
<td>Lederle Laboratories, Pearl River, N. Y.</td>
<td>b</td>
<td>i.p.</td>
<td></td>
</tr>
<tr>
<td>THIO</td>
<td>Thio-TEPA</td>
<td>Lederle Laboratories, Pearl River, N. Y.</td>
<td>b</td>
<td>i.p.</td>
</tr>
</tbody>
</table>

* Commercial drugs in injectable form were obtained from a pharmacy unless otherwise noted.
* Supplied as a solution or diluted with water, ethanol, or 0.9% NaCl solution according to directions on package.
* Supplied in powder form as a gift from listed source.
* Dissolve 20 mg in 0.4 ml absolute ethanol. Add 0.6 ml Klucell (0.3% hydroxypropyl cellulose).
* Dissolve 10 mg in 0.5 ml of 70% ethanol. Add 4.5 ml of 0.1 M sodium phosphate (pH 6.8). Inject quickly.
* Dissolve in 0.1% NaCl solution and 1% mannitol.
* Similar results were obtained with both routes of injection.
* Similar results, except for higher LD50 with i.v. injection, were obtained with both routes.
M. L. Meistrich et al.

(Glogau and Co., Inc., Melrose Park, Ill.), controls were run to demonstrate that these vehicles alone had no damaging effect on spermatogenesis.

Analysis of Testicular Cell Killing

The protocol developed in a previous study (27), used here essentially with only minor modifications, is presented below.

Eleventh Day after Injection. One mouse in each dose group was killed for histological studies of testicular sections. The presence of normal numbers, markedly reduced numbers, or the absence of each cell type at each stage of the cycle of the seminiferous epithelium (38) was recorded. The stage of spermatogenesis of each cell at the time of treatment was determined. In this manner, the precise stages of differentiation of spermatogenic cells sensitive to the cytotoxic drug could be determined.

Twenty-ninth Day after Injection. Testes from at least 3 mice from each group were homogenized separately and sonicated, and sperm heads were counted. In order to facilitate more rapid processing of smaller samples, a PT7 head on the Polytron homogenizer (Brinkmann Instruments, Inc., Westbury, N. Y.) and a cup horn on the Branson sonicator (Heat Systems-Ultrasonics, Inc., Plainview, N. Y.) with a circulating cold water bath were used. The number of sperm heads per testis is a measure of the survival of the differentiated spermatogonia. The spermatogonia which differentiate into sperm heads 29 days later include the type A1 (in Stage VIII) through the intermediate spermatogonia (at the start of Stage IV).

Thirty-fifth Day after Injection. When appreciable stem cell killing was observed by sperm head counting, testes were also prepared for histological analysis. Counts of repopulated tubular cross-sections were then performed (48). The number of spermatogenic colonies per tubular cross section (SSI) was calculated from the fraction of repopulated tubules (RI) by applying the Poisson statistical correction, SSI = -log0(1 - RI).

Fifty-sixth Day after Injection. Sperm heads counts were obtained from at least 3 mice/dose group. The number of sperm heads on Day 56 is highly correlated with survival of testicular stem cells. As demonstrated previously, this assay may be insensitive to killing of up to 80% of the stem cells (28).

Animal Mortality

All drugs were used in concentrations up to the lethal doses. LD50

![Cell Type Spermatogonia Spermatocytes](chart)

Charts 1 and 2. Specific stages of spermatogenic cells killed by various drugs as determined by analysis of histological sections 11 days after injection. A, all cells killed; B, some cells killed; C, no effect; n, no cells killed but many of the resulting spermatids apparently diploid. A1, A2, and A3 represent A-isolated, A-paired, and A-aligned spermatogonia, respectively. L, represents intermediate spermatogonia. PI, L, and Z represent preleptotene, leptotene, and zygotene spermatocytes, respectively.
values for animal mortality were calculated for survival at 29 days by the logit method of analysis.

Preparations for Cytogenetic Analysis

At 1, 3, 5, 11, 29, 56, and 80 days after injection, one animal from each drug group was sacrificed, and cytological preparations were made (14, 21). After removal of the tunica, the tubules were minced in 0.2 ml of balanced salt solution. The cells were suspended in a tissue culture medium, centrifuged, and then treated in 12 ml of hypotonic solution of 0.075 M KCl for 20 min at 37°. The cells were pelleted and fixed in a Carnoy’s solution. Conventional air-dried preparations were made and stained in 5% Giemsa for 10 min. Fifty cells from each mouse were scored. Some time points could not be obtained as a result of animal mortality as well as the absence of diakinesis meiotic-metaphase I cells due to spermatogonial killing. Because of the low numbers of samples in this preliminary study, data were pooled as follows. Diakinesis-meiosis I metaphase cells obtained on Days 1 to 11 were derived from cells in the spermatocyte stages at the time of treatment. Values obtained on Days 29 to 80 were derived from cells which were stem spermatogonia at the time of treatment. The signifi-

Charts 3 to 6. Relationship between testicular sperm head count/mouse (fraction of untreated control) and injected dose of various drugs displayed on log-log plots. Sperm head counts performed 29 days after injection (○) represent the number of surviving differentiated spermatogonia. Sperm head counts obtained at 56 days (○) represent the surviving stem cells. Points, geometric means; bars, S.E.; arrows, LD₅₀ dose for each drug.

JANUARY 1982 125

Downloaded from cancerres.aacrjournals.org on June 1, 2017. © 1982 American Association for Cancer Research.
cance in the difference between control and treated groups was determined by a χ² test.

RESULTS

Animal Toxicity. LD₅₀ values for animal mortality were determined (Table 2). Most deaths occurred between 4 and 15 days. Usually no general toxicity was observed at doses below the LD₅₀'s. High doses of MTX (≥750 mg/kg) and PCB (≥400 mg/kg) caused the animals to collapse after injection, but they recovered within 1 day. High doses of BCNU (≥33 mg/kg), PRED (≥800 mg/kg), and THIO (≥23 mg/kg) affected the motor coordination of the mice shortly after injection. Weight loss was apparent after high doses of CCNU (≥40 mg/kg). Cytotoxic effects on the testis cells were observed at lower doses than was animal toxicity. In addition, different drugs showed specific patterns for spermatogenic cell killing. Therefore, systemic toxicity probably has at most a minor effect on

---

**Graphs and Data:**

- [Graph 1: Daunorubicin]
- [Graph 2: CCNU]
- [Graph 3: Cis-Platinum]
- [Graph 4: Mechlorethamine]
- [Graph 5: Procarbazine]
- [Graph 6: 5-Fluorouracil]
Chemotherapeutic Drug Effects on Testis

Table 2

Toxicity of acute doses of antineoplastic agents to mice and testis cells

<table>
<thead>
<tr>
<th>Agent</th>
<th>LD50 for animal mortality (mg/kg)</th>
<th>LD50 for differentiated spermatogonia (mg/kg)</th>
<th>LD50 for stem spermatogonia (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>1.0</td>
<td>0.3</td>
<td>1.3</td>
</tr>
<tr>
<td>BCNU</td>
<td>60</td>
<td>11</td>
<td>42</td>
</tr>
<tr>
<td>CCNU</td>
<td>60</td>
<td>9</td>
<td>&gt;40</td>
</tr>
<tr>
<td>CHL</td>
<td>34</td>
<td>4</td>
<td>28</td>
</tr>
<tr>
<td>CDDP</td>
<td>11</td>
<td>1.1</td>
<td>&gt;10</td>
</tr>
<tr>
<td>DNR</td>
<td>18</td>
<td>2.2</td>
<td>&gt;20</td>
</tr>
<tr>
<td>5-FU</td>
<td>530</td>
<td>67</td>
<td>750</td>
</tr>
<tr>
<td>HN2</td>
<td>4.4</td>
<td>0.8</td>
<td>&gt; 4</td>
</tr>
<tr>
<td>6-MP</td>
<td>80</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>MTX</td>
<td>800</td>
<td>260</td>
<td>&gt;750</td>
</tr>
<tr>
<td>MTC</td>
<td>5</td>
<td>0.5</td>
<td>3</td>
</tr>
<tr>
<td>PRED</td>
<td>&gt;1000a</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>PCB</td>
<td>800</td>
<td>53</td>
<td>430</td>
</tr>
<tr>
<td>THIO</td>
<td>28</td>
<td>0.85</td>
<td>11</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>750 rad</td>
<td>53 radb</td>
<td>320 radc</td>
</tr>
</tbody>
</table>

a The LD50 for i.m. injection was about 600 mg/kg, but only a few animals died with i.p. injections of 800 or 1000 mg/kg.

b From Li and al. (35).

c From Lu et al. (28).

Killing of spermatogenic cells.

Semiquantitative Histological Analysis. Histological analysis of testes prepared from mice killed 11 days after treatment was used to obtain an overall view of drug-induced histopathology as well as to determine the specific stages at which spermatogenic cells were drug sensitive. No alterations were observed in the interstitial tissue or the structure of the tubules; the damaging effect of the drugs was primarily to the germinal cells.

The sensitivity of cells in the various spermatogenic stages was determined from histological sections (Charts 1 and 2). The general pattern of cytotoxicity observed was that differentiated spermatogonia were the most sensitive cell type, whereas the spermatocytes and spermatids were resistant. Three exceptions were found. PRED produced no detectable cell killing, even at the highest doses tested. 5-FU was the only drug which had an effect on post spermatogonial cells at doses which were insufficient to kill spermatogonia. Doses of 50 mg of 5-FU per kg affected early pachytene spermatocytes such that they produced appreciable numbers of apparently diploid round spermatids after passing through meiosis. Zygote (but not late preleptotene or early leptotene) spermatocytes are sensitive towards high doses of 5-FU, because the damage to spermatocytes is expressed as cell killing mainly when the cells try to pass through their meiotic divisions.1 Eleven days after injection, the preleptotene and early leptotene cells would still be in the diplotene and diakinesis stages. CDDP, when given in a high dose, resulted in killing of some cells in all stages, from zygotene spermatocyte through Step 5 spermatid (the latest stage analyzable by this technique). Since the spermatocytes killed by CDDP were only those in the adluminal compartment (40) (behind the barrier formed by the Sertoli cells), the results could indicate that some damage to the function of the Sertoli cells occurred. With several drugs, including CDDP, HN2, MTC, and THIO, an increased number of degenerating cells in the process of meiotic division were observed.

Several patterns of differential sensitivity of the spermatogonia were observed. BCNU, MTC, PCB, HN2, and THIO preferentially killed A3, A4, and intermediate spermatogonia at low doses with some effect on cells up to the PI spermatocyte stage. On the other hand, 5-FU, MTX, and ACT preferentially killed A1 and A2 spermatogonia with the latter 2 having no effect on the preleptotene cells. At higher doses of BCNU, MTC, PCB, and THIO, killing of A4 and A5 spermatogonia was observed with less effect on the A6 spermatogonia. The killing of A6 spermatogonia by these 4 drugs is also manifest in assays for stem cell killing described below.

Several types of abnormalities in spermatids were observed as a result of drug treatments. ACT, CCNU, CDDP, DNR, 5-FU, 6-MP, MTC, and PCB produced some large round spermatids, which we presume were diploid. Other drugs, BCNU, CHL, HN2, MTX, and THIO, did not produce such cells even at the highest doses used. Another type of spermatid abnormality, observed only after CDDP, was the formation of binucleate spermatid, with nuclei fused at their acrosomes. BCNU, CCNU, PCB, and THIO caused a delay in spermiogenesis; spermatids were present in Stage IX and X tubules. Several drugs resulted in the production of abnormally shaped elongated spermatids. PCB and 6-MP produced a high frequency of such cells.

Quantitative Measurement of Survival of Differentiated Spermatogonia. Testicular sperm head counts obtained 29 days after injection (Charts 3 to 6) indicated that differentiated spermatogonia were sensitive to all drugs except PRED and 6-MP. Only 2 drugs, 5-FU and PCB, could kill nearly all of these cells (10^-3 survival). LD50 values for killing of the differentiated spermatogonia by various drugs are presented in Table 2.

Quantitative Measurement of Stem Cell Survival. Stem cell survival was determined by sperm head counts 56 days after treatment (Charts 3 to 6). Several drugs, including CCNU, CDDP, HN2, 6-MP, MTX, and PRED, did produce, at the highest dose point, up to 25% decline in sperm counts, which appeared to be statistically significant. However, such small decreases could result from nonrandom variations in different groups of mice and do not demonstrate significant stem cell killing by these drugs. Seven drugs, ACT, BCNU, CHL, DNR, 5-FU, MTC, and PCB, reduced sperm head counts to between 30 and 60% of controls, indicating significant stem cell killing. Only one drug, THIO, produced strong stem cell toxicity. None of the drugs in this group produced the extent of stem cell killing observed previously with ADR (Table 3).

Stem cell killing by THIO was also demonstrated by counting nonrepopulating tubule cross-sections in histological preparations (Chart 7). Only doses above 20 mg/kg, which reduced sperm production to 5% at 56 days, were sufficient to produce an appreciable number of nonrepopulating tubules. A similar relationship between the 2 methods for assaying stem cell survival had been shown for ionizing radiation and ADR (32).

Production of Chromosomal Aberrations. Four drugs from this group (BCNU, THIO, MTC, and CDDP) were selected for study of the chromosomal aberrations produced (Table 4). BCNU and CDDP induced significant increases in the frequencies of univalents recovered at meiosis from treated spermatocytes. CDDP also increased the frequency of autosomal univalents resulting from treated stem cells. A significant increase in chromosome breakage recovered at meiosis I was also observed with treatment of spermatocytes with any of the drugs, but only BCNU-treated stem cells yielded a significantly
Table 3
Summary of sensitivity of spermatogenic cells to cytotoxic effects of single doses of antineoplastic agents
[data from present study, Lu and Meistrich (27), and Lu et al. (28)]

<table>
<thead>
<tr>
<th>Effect on differentiating spermatogonia</th>
<th>Moderate (0.1 &lt; R &lt; 0.2)</th>
<th>Strong (R &lt; 0.1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not significant (S &gt; 0.7)</td>
<td>PRED MTX (&gt;3)</td>
<td>CCNU (&gt;4)</td>
</tr>
<tr>
<td></td>
<td>6-MP Bleomycin (&gt;2.5)</td>
<td>CDDP (&gt;9)</td>
</tr>
<tr>
<td></td>
<td>Vinblastine (&gt;1.6)</td>
<td>Hydroxyurea (&gt;50)</td>
</tr>
<tr>
<td></td>
<td>Vincristine (&gt;3)</td>
<td></td>
</tr>
<tr>
<td>Some killing (0.3 &lt; S &lt; 0.6)</td>
<td>ACT (4)</td>
<td>BCNU (4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHL (7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DNR (4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5-FU (11)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MTC (6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderately strong killing (S = 10^{-4})</td>
<td></td>
<td>THIO (17)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>y-Radiation (6)</td>
</tr>
<tr>
<td>Very effective killing (S = 10^{-7})</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* R = LD_{50} for differentiated spermatogonia + LD_{50} for animal mortality.
* S = sperm head counts at 56 days at maximal dose.
* Numbers in parentheses, LD_{50} for stem cell + LD_{50} for differentiated spermatogonia.
* Kills spermatocytes and spermatids at high doses.
* Early pachytenate spermatocytes are extremely sensitive.

increased incidence of breaks at meiosis. THIO was the only drug which produced a significant number of multivalent translocations when spermatocytes were treated. One translocation was recovered from THIO-treated stem spermatogonia.

**DISCUSSION**

The results on germ cell cytotoxicity obtained here can be compared with previous studies of several drugs. Our results are consistent with the reported effects of PCB on CDF, mice (24), 101 × C3H mice (12), DBA mice (45), and rabbits (7); MTC on 101 × C3H (1, 13, 22), NMRI (30), CF, (16), C3H (42), and BALB/c (19) mice; 6-MP on 101 × C3H mice (18); and 5-FU on 101 × C3H mice (22). The apparent discrepancies are listed below. With 101 × C3H mice, 6-MP showed a much higher (about 270 mg/kg) LD_{50} for animal mortality (18). Measurements of the ability of sperm to fertilize ova indicated that PCB- (12) or MTC- (13, 22) treated spermatocytes were incapable of producing fertile sperm. Thus, the lack of cell killing

---

Table 4
Percentage of cells with chromosome damage in diakinesis-meiosis I figures derived from cells treated in prior stages

<table>
<thead>
<tr>
<th>Cell stage treated</th>
<th>Spermatocytes</th>
<th>Stem cells</th>
</tr>
</thead>
</table>
|                    | Dose (mg/kg)  | Cells scored | XY univalents | Auto-
|                    |               |             |              | somal univalents | Breaks | Translocat |
| Control            | 0             | 400         | 15           | 5 | 0 | 0 |
| BCNU               | 33            | 200         | 22           | 9 | 4 | 0 |
| THIO               | 20            | 150         | 10           | 9 | 3 | 0 |
| MTC                | 5             | 200         | 18           | 4 | 2 | 0.5 |
| CDDP               | 10            | 200         | 24           | 9 | 4 | 0 |
|                    |               |             |              |   |   |   |
|                    |               |             |              |   |   |   |

* Abnormalities observed in diakinesis-meiosis I metaphase were derived from spermatocytes treated between 1 and 11 days before sacrifice.
* Abnormalities observed were derived from stem cells treated at least 26 days before sacrifice.
* Significantly different from control at P = 0.05.
* Significantly different from control at P = 0.01.
* Significantly different from control at P = 0.001.
Chemotherapeutic Drug Effects on Testis

does not mean that fertile sperm must be produced. The doses required to reduce $^{3}H$thymidine incorporation in rat testes 1 day later by 50% (23) differ from our results. Comparing doses on a mg/sq m basis (17), our LD$_{50}$ values for killing differentiated mouse spermatogonia by cyclophosphamide, CCNU, CHL, THIO, and PCB are 5- to 10-fold lower than the results of the DNA synthesis inhibition assay. The discrepancy may be a result of the different stages of spermatogonia being assayed, rather than a species difference. In general, our results are comparable to data obtained with other strains of mice and with rabbits.

Only damage to the germinal cells was detected in this study. Leydig cells, in mice treated with chemotherapeutic agents, appeared normal. Previously (33), we had shown that Leydig cell atrophy can be recognized under conditions which markedly suppress leuteinizing hormone levels. Furthermore, chemotherapy did not produce clinically significant damage in nongerminal cells of the testis, pituitary, or hypothalamus (8, 43). Presumably, testosterone synthesis by Leydig cells is still active after drug treatment, but this should be checked in future studies.

It is important to know if the survival of stem spermatogonia, spermatocytes, and spermatids indicates resistance of these cells or lack of drug penetration into the seminiferous tubules. All drugs tested, with the exception of PRED, killed differentiated spermatogonia, which are in the same compartment of the tubules as the stem cells. Thus, drug penetration to the stem cell is not a limitation. The spermatocytes and spermatids, on the other hand, are separated from the spermatogonia by Sertoli cell junctions (40). However, data on chromosomal aberrations, mutagenesis, ultrastructural alterations, and binding of radioactive drugs demonstrate that BCNU, CDDP, PCB (12), MTC (13), ACT (5), THIO (38), and HN2 (38) can penetrate the blood-testis barrier to reach spermatocytes and spermatids. Thus, the resistance of these cells cannot be ascribed to a complete lack of drug penetration. A more likely explanation for the greater sensitivity of differentiated spermatogonia is that most chemotherapeutic drugs preferentially kill actively cycling cells (11).

The cytotoxic effectiveness of different drugs towards the differentiated and stem spermatogonia were compared in 2 ways. First, the ratio of LD$_{50}$ doses for differentiated spermatogonia to those for animal mortality ($R$) and the survival of stem cells at the maximal dose ($S$) were used to classify the various agents (Table 3). There is limited correlation between this classification of drugs and their mechanisms of action. The Vinca alkaloids, which are mitotic poisons, are not toxic to stem cells, presumably because these cells are very slowly cycling (37). Similarly, drugs that affect the availability of DNA precursors (6-MP, MTX, 1-$\beta$-o-arabinofuranosylcytosine, and hydroxyurea) are also nontoxic to stem cells. The one exception is 5-FU, which also acts by interfering with RNA synthesis. Another explanation for the effectiveness of 5-FU is that its active metabolite has a much longer intracellular half-life (7 to 9 days) than, for example, that of 1-$\beta$-o-arabinofuranosylcytosine (34, 41). The stem cells may be triggered into cycle by 5-FU while the drug is still active. All alkylating agents (CCNU, HN2, BCNU, CHL, CDDP, cyclophosphamide, MTC, and THIO) showed strong killing of differentiated spermatogonia but varying degrees of stem cell killing. A second method for classifying agents was by the ratio of LD$_{50}$ for stem cell killing to that for differentiated spermatogonia killing (Table 3). This ratio is greater than one in all cases, indicating the greater sensitivity of the rapidly dividing spermatogonia, than of the stem cells. The ratio is generally low for intercalating antibiotics (ADR, ACT, and DNR), higher for alkylating agents, and the highest for antimetabolites (1-$\beta$-o-arabinofuranosylcytosine, hydroxyurea, and 5-FU). The high ratio in the last category is expected since these drugs primarily affect DNA synthesis and should be more specifically cytotoxic for differentiated spermatogonia.

Next the question of whether or not data on cytotoxic effects observed in the mouse can be applied to humans should be considered. Table 5 represents an attempt to compare the experimental results with clinical data. The most cytotoxic drug, among those tested, towards murine stem cells, was ADR. In contrast, this drug did not produce permanent sterility in humans. On the other hand, combination chemotherapy with MOPP or MVPP produced permanent azoospermia in most patients. Of these agents, only PCB and perhaps HN2 were even slightly cytotoxic to mouse testicular stem cells. We estimate that 6 courses of MOPP or 8 courses of MVPP therapy will reduce mouse testicular stem cell survival to 1% or 0.03%, respectively. Recovery of sperm production in the mouse occurred after these levels of stem cell killing (32). It is impossible to compare the experimental and clinical data in the case of cyclophosphamide, since sufficient dose could not be administered in a single injection to produce stem cell killing. In the case of CHL, a crude calculation of the dose necessary to reduce stem cell survival to $10^{-5}$ does provide a good estimate of the dose at which permanent azoospermia is observed in humans.

There are several possible explanations for the discrepancies between the experimental and clinical data. (a) The response of the regenerating stem cell may differ from that of the stem cell in steady state; single injections of drug may not yield the same results as multiple injections. (b) Synergistic and antagonistic effects between drugs may occur during combination chemotherapy; the use of single drugs may not be representative. (c) The action of these drugs in humans may differ markedly from that in the mouse. In the case of ADR, the third possibility is most likely. An interspecies comparison of the pharmacokinetics, stem cell killing, and duration of azoospermia produced by this drug should be performed to understand the causes of this discrepancy. With cyclophosphamide and CHL, protracted administration over several months is necessary to obtain appropriate experimental doses to properly compare with the clinical data. In the case of MOPP or MVPP, drugs should be given to mice according to their clinical schedule, first singly and then in combination. In addition, experiments must be designed to understand the fundamental reasons for differences in sensitivity of testicular stem cells to single and fractionated treatment.

The cytogenetic effects of anticancer drugs can also have serious consequences. Translocations could result in heritable mutations. Breaks could cause embryonic lethality. The genetic consequences of univalency are unknown, but it is possible that it could result in nondisjunction. In general, greater damage is induced by chemicals when cells are treated as spermatocytes than as stem cells (2, 6, 26). Treatment of stem cells with CDDP, nevertheless, did significantly increase univalency. Previous studies had indicated that BCNU (47) but not MTC (1) treatment of stem cells could increase univalency. Several

JANUARY 1982 129

Downloaded from cancerres.aacrjournals.org on June 1, 2017. © 1982 American Association for Cancer Research.
agents appeared to increase the frequency of breaks recovered in spermatocytes after treatment of stem cells, as observed previously with ADR (4). In addition, the observation of a translocation induced in stem cells by THIO indicates that the genetic damage to stem cells may be expressed in the resulting spermatocytes, as was the case of ADR. A previous study (29) had also indicated induction of translocations in spermatogonia by THIO. Thus, the 2 agents that were most cytotoxic towards stem cells were also most genotoxic. These results demonstrate the importance of pursuing further study of the mutagenicity of chemotherapeutic agents on germ cells.

In conclusion, this study has characterized the differences in sensitivity of specific spermatogenic cell types to 14 chemotherapeutic agents. Quantitative measurements of stem cell survival represent a first step in an attempt to develop an experimental system to test the sterilizing effects of chemotherapeutic drugs.

ACKNOWLEDGMENTS

We thank Debbie Palmatary and her staff for the supply and care of the mice used in this study, Betty Reid and Cheryl Collie-Bruyere for technical assistance, Ann McCarver for preparation of the manuscript, and Dr. T. C. Hsu for guidance in the cytogenetic studies.

REFERENCES

Chemotherapeutic Drug Effects on Testis


Damaging Effects of Fourteen Chemotherapeutic Drugs on Mouse Testis Cells

Marvin L. Meistrich, Marcia Finch, Miguel F. da Cunha, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/42/1/122

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.